Increased Expression of miR-202-3p in Patients with Relapsing-Remitting Multiple Sclerosis
Authors
Abstract:
Background and objectives: One of the latest studies in the genetics field is the evaluation of role of micro-RNAs as a biomarker for diagnosis of multiple sclerosis (MS), which is a demyelinating disease of the central nervous system (CNS) and emerges in the form of numerous small and large plaques in white matter in the brain and spinal cord. This disease could be associated with several complications, including reduced vision, spasticity and imbalance, and impaired sphincter control. MiR-202-3p is an intronic miRNA located in the ADA (Adenosine Deaminase) gene, which is the main enzyme involved in the pathway for the conversion of adenosine into inosine. Moreover, ADA regulates the inflammatory response and protection of tissue from damage as a strong complementary mechanism. This study aimed to evaluate the expression level of miR-202-3p in individuals diagnosed with relapsing-remitting multiple sclerosis (RRMS) and healthy individuals in Isfahan, Iran. Methods: This analytical-observatory study was performed on 49 RRMS patients and 52 healthy individuals with no history of autoimmune and inflammatory diseases. Total RNA was extracted from blood lymphocytes by Ficoll and Trizol. Afterwards, cDNA was formed using a special miRNA cDNA kit, followed by the application of Real-time RT PCR to measure the expression of miR-202-3p in healthy individuals and patients. Results: According to the results, the miR-202-3p expression was higher in patients, compared to healthy individuals (P=0.006). In addition, the sensitivity and diagnostic value of this miRNA in receiver operating characteristic (ROC) curve analysis were equal to AUC=0.80 (area under the curve). Conclusion: In line with other studies, our findings demonstrated that miR-2023p can be used as a biomarker in the diagnosis of MS. In addition, it seems that miR-202-3p acts as an immunosuppressant by inhibiting ADA gene, which regulates various processes related to inflammatory response and maintenance of tissue from damage.
similar resources
Altered Expression of Circulating miR-377 and miR-98 in Relapsing-remitting Multiple Sclerosis
Background and Aims: Multiple sclerosis (MS) has been assumed to be a complex and indecipherable disease, and poorly understood with regard to etiology which is characterized by relapses and remissions. The expression of microRNAs (miRNAs) is known to be associated with the regulation of immune responses. Recently, investigations have reported that miRNA expression profiles in blood cells becom...
full textDistinctive deregulation of miR-27a and miR-27b in relapsing remitting multiple sclerosis
Introduction: Previous studies have proposed that microRNAs (miRNAs) expression might be responsible for immunological features associated with multiple sclerosis (MS) pathogenesis. We aimed to elucidate the alternation in miR-27a and miR-27b expression in relapsing-remitting multiple sclerosis (RRMS) patients compared to the healthy subjects. Materials and methods: In this study, the expressi...
full textCirculating miR-193b-3p and miR-376a-3p Involved in Iranian Patients with Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disease that affects the central nervous system. MicroRNAs (miRNAs) are small non-coding RNAs that are usually 18-24 nucleotides long, which may have a pivotal role in the expansion of many complex diseases. The objective of this study was to evaluate the transcript levels of miR-193b-3p and miR-376a-3p in relapsing-remitting multiple sclerosis (RRMS) ...
full textAlteration of OGG1, MYH and MTH1 genes expression in relapsing-remitting multiple sclerosis patients
Introduction: Previous studies revealed that oxidative stress is elevated in multiple sclerosis (MS). It can harm to biological macromolecules such as DNA. However, the molecular mechanism in protection of genetic information from DNA damages is not clear in MS disease. In this study the expression level of some important genes of OGG1 and MYH involved in base excision repair pathway and, MTH1 ...
full textSafety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...
full textComparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis
Background: The present study aimed to compare the clinical efficacy and safety profile of Ziferon and Betaferon. Objectives: In total, 41 consecutive patients with relapsing forms of Multiple Sclerosis (MS) were selected from the MS outpatient clinic affiliated to Tehran University of Medical Sciences. The patients were randomly assigned into two groups. Methods: Each group either received Z...
full textMy Resources
Journal title
volume 6 issue 4
pages 8- 18
publication date 2018-12
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023